Related Experiment Videos
Issues and challenges with antithrombotic therapy in diabetic patients with acute coronary syndromes
1Mayo Clinic and Foundation, 200 1st Street SW, Rochester, MN 55905, USA. barsness.gregory@mayo.edu
Insights
Diabetes mellitus significantly increases risks for patients with acute coronary syndromes due to coagulation issues. Antithrombotic therapies show promise, but optimal dosing for diabetics needs further study.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Hematology
Background:
- Diabetes mellitus is linked to increased morbidity and mortality in acute coronary syndromes (ACS).
- Diabetic patients exhibit impaired endothelial function, platelet activity, and coagulation factors, contributing to higher cardiovascular risk.
- Limited research has focused on specific therapeutic interventions for diabetic patients experiencing ACS.
Purpose of the Study:
- To review the impact of diabetes mellitus on coagulation in ACS patients.
- To evaluate the efficacy and safety of antithrombotic therapies in this high-risk population.
- To highlight the importance of primary prevention and risk factor modification.
Main Methods:
- Literature review of studies investigating diabetes, coagulation, and ACS.
- Analysis of existing data on antithrombotic treatments in diabetic ACS patients.
- Examination of risk factor modification strategies.
Main Results:
- Diabetes mellitus significantly elevates ACS-related risks due to prothrombotic states.
- Antithrombotic therapies beneficial in the general population appear effective in diabetic ACS patients.
- Optimal antithrombotic dosing for safety and efficacy in diabetics requires further investigation.
Conclusions:
- Diabetic patients with ACS face heightened risks primarily due to coagulation disturbances.
- While antithrombotic agents show promise, personalized dosing is crucial.
- Primary prevention and aggressive risk factor management are key for long-term outcomes in diabetic cardiovascular disease.
Abstract:
Diabetes mellitus is associated with significant morbidity and mortality in the setting of acute coronary syndromes. This increased risk is attributable, in large part, to the derangements in coagulation that can accompany the diabetic disease state. Patients with diabetes mellitus have disturbances in endothelial function, platelet function, and coagulation factors. Until recently, there has been little direct exploration of therapeutic measures to improve outcome specifically among diabetic patients with acute coronary syndromes. Fortunately, antithrombotic therapies that have proven benefit in the general population also seem to be beneficial among patients with diabetes, although optimal dosing for improved safety and efficacy in this population has yet to be established for many of these agents. Primary prevention strategies and strict attention to risk factor modification hold the greatest promise for improving long-term outcome.